---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-22-000064"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:59:11.273313+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q4 revenue $34.7M (+68% YoY); 2021 revenue $99.7M (+76%); 2022 guidance $143-150M reaffirmed

## Summary
- Q4 2021 net revenue $34.7M, up 68% from Q4 2020; full-year revenue $99.7M, up 76% over 2020.
- Cash and cash equivalents $146.3M at Dec 31, 2021, including $68.7M from first tranche of $125M term loan.
- Reaffirmed FY2022 revenue guidance of $143-150M (43-50% YoY growth); expects adjusted gross margin 58-61%.
- Added 400 new accounts in Q4 and 1,400 in 2021; total accounts >7,000 with reorder rate >70%.
- Phase II extra-strength Jeuveau study on track for first patient Q1 2022; Nuceiva EU launch planned Q3 2022.

## SEC filing metadata
- accession: 0001570562-22-000064
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000064/0001570562-22-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000064/eols-20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-22-000064
- JSON: https://secwatch.observer/filing/0001570562-22-000064.json
- Plain text: https://secwatch.observer/filing/0001570562-22-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.